Navigation Links
InspireMD to Commence Trading as a Public Company Under Ticker Symbol "NSPR"
Date:5/5/2011

TEL AVIV, Israel, May 5, 2011 /PRNewswire/ -- InspireMD, Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), the developer of the MGuard™ mesh protective stent system, announced today that it has been approved by FINRA to have its stock quoted on the Over-the-Counter Bulletin Board (OTCBB) under the symbol "NSPR".

In addition, on March 31, 2011, InspireMD concluded a $9.7 million PIPE offering in which (i) it raised approximately $9.0 million of cash and (ii) approximately $0.7 million worth of debentures were converted. In connection with the PIPE, InspireMD issued 6,454,002 shares of common stock and five year warrants purchasing up to 3,226,999 shares of common stock at an exercise price of $1.80 per share. On April 18, 2011, InspireMD raised an additional $1,425,000, issuing 950,000 shares and 475,000 warrants.

Palladium Capital Advisors LLC, acted as the placement agent for the capital raise and advised the company on the merger.

InspireMD, through its subsidiaries, is a high growth medical device company focusing on the development and commercialization of its proprietary stent platform technology: MGuard™. The Company has created a patent-pending micron mesh technology that wraps a stent, addressing embolic protection thereby reducing Major Adverse Cardiac Events [MACE] by filtering debris and minimizing vessel injury by distributing strut pressure. MGuard™ has been implanted in thousands of patients with encouraging clinical results in Europe and Latin America. MGuard™ is a solution for high-risk Acute Coronary Syndrome (heart attack) patients - a market of over two million patients per year. The Company received CE Mark approval in Europe and has distribution agreements in more than 30 territories, including Europe, Asia, Australia, Brazil, the Far East, India, and South America. The Company is currently conducting a randomized trial in Europe, Latin America and South Africa, chaired by Dr. Gregg Stone, to sup
'/>"/>

SOURCE InspireMD
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. InspireMD Boosts MGuard Production Capacity
2. InspireMD Becomes a Supporting Organization in the Growing Stent for Life Initiative
3. For the First Time, at EuroPCR, InspireMD Will Provide a Sneak Preview of the Next Generation MGuard Prime(R), a State of the Art Net Protective Cobalt Chromium Stent System
4. InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients
5. OncoMed Pharmaceuticals Announces FDA Clearance to Commence Phase 1 Testing of Anti-Cancer Stem Cell Therapeutic OMP-18R5
6. Express Scripts Announces Intention to Commence a Debt Offering
7. Marinus Pharmaceuticals Announces Commencement of Phase 2 Trial of Ganaxolone for the Treatment of Posttraumatic Stress Disorder
8. Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
9. Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt®
10. CryoLife Commences Tender Offer for All Outstanding Shares of Cardiogenesis Corporation
11. Unilife Commences Initial Production of Unifill Prefilled Syringe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Research and Markets  has announced the addition ... report to their offering. ... hollow needle commonly used with a syringe to inject ... from it. A hypodermic needle is used for rapid ... be ingested. Hypodermic needles are broadly classified into non-safety ...
(Date:7/11/2014)... , July 11, 2014 ... at 4,396.20, down 0.52%, the Dow Jones Industrial Average finished ... closed at 1,964.68, down 0.41%. The losses were broad based ... negative. The S&P 500 Health Care Sector Index ended the ... 2.75% in the last one month. Investor-Edge has initiated coverage ...
(Date:7/11/2014)... , July 11, 2014  Veran Medical ... announced today the positive, cost-effective final results ... SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous biopsy ... percutaneous approach to biopsy when a traditional ... and physicians experience positive financial outcomes when ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Veran Medical Publishes Lung Cancer Patient Management Study 2
... 4, 2011 Reportlinker.com announces that a new ... European Market for Cardiac Rhythm ... http://www.reportlinker.com/p0488652/European-Market-for-Cardiac-Rhythm-Management-Electrophysiology--Ablation-Devices-2011.html European Market ... 2011 (15 countries) In 2010, ...
... 2011 Reportlinker.com announces that a ... in its catalogue: ... – Bone Grafting and Hyaluronic Acid ... http://www.reportlinker.com/p0488653/European-Markets-for-Orthopedic-Biomaterials-2011-–-Bone-Grafting-and-Hyaluronic-Acid-Viscosupplementation-15-Countries.html The ...
Cached Medicine Technology:Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 2Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 3Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 4Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 5Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 6Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 7Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 8Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 9Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 10Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 11Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 12Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 13Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 14Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 15Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 16Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 17Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 18Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 19Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 20Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 21Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 2Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 3Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 4Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 5Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 6Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 7Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 8Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 9Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 10Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 11Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 12Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 13Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 14Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 15Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 16
(Date:7/13/2014)... By Serena Gordon ... -- A new type of sensor for people with ... body using saliva instead of blood, researchers report. Scientists ... successfully tested it using artificial saliva. It uses light, metal ... blood sugar. "Everybody knows that diabetics have to prick ...
(Date:7/13/2014)... Recently, 2014QuinceaneraDresses.com, the distinguished special occasion dress manufacturer ... gorgeous Quinceanera dresses . , In ... outfits is huge. Therefore, 2014QuinceaneraDresses.com is striving to ... released dresses are made according to the latest ... , It is worthy of mention that ...
(Date:7/13/2014)... 13, 2014 Epidemiologists forecast an increase ... 6MM, from 8,062 diagnosed incident cases in 2013 to ... Growth Rate (AGR) of 4.35%, during the forecast period. ... of diagnosed incident cases of aGVHD in the 6MM, ... the lowest number of diagnosed incident cases of aGVHD, ...
(Date:7/13/2014)... 13, 2014 Wright & Schulte LLC ... been scheduled in July of 2015, in U.S. District ... are in the discovery process in the South ... is presiding over the multidistrict litigation (MDL). The complaints ... of individuals who allege that they took the statin ...
(Date:7/13/2014)... 2014 Hope Palliative & Hospice Care announced ... group at the Tamarack Senior Living Community in Palatine, IL. ... A.M. on the 3rd Wednesdays of every month. This ... Tamarack Community located at 55 S. Greeley St. Palatine, IL ... there is no cost for the group. , “A ...
Breaking Medicine News(10 mins):Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2
... drug to the usual three-drug HIV treatment regimen is not ... the HIV load// or the drug resistance, the new study ... JAMA, a theme issue on HIV/AIDS. ,Roy M. ... New York, presented the findings of the study today at ...
... used HIV treatments, researchers found one triple-drug therapy was ... the blood when used as a first-line treatment. Results ... among three different therapies the optimal approach for patients ... reported at the XVI International AIDS Conference (AIDS 2006). ...
... new study published in the September 15, 2006 issue ... Society, says that African-Americans are least likely to// ask ... says that the level of interest displayed by Caucasian ... This fact may lead to the African-Americans making less-informed ...
... has said that better quality drugs and child medication ... ,Speaking to Agence France-Presse (AFP) ... in Toronto he said, "We definitely need to improve ... talking to pharmaceuticals. We definitely want to buy second-line ...
... radical changes in business with tangible growth in Asian countries, ... of a jet setting pace, so much a part of ... a demographic crisis, with a rampant spread of mental health ... palpable, and is attributed to the high stress in the ...
... in on a weakened scout cell, which is known to ... out that cancer in some of the transplant patients shows ... for the immune system. Researchers are optimistic that by ... find ways to prevent the onset of cancer. The reason ...
Cached Medicine News:Health News:Four-Drug AIDS Treatment Regimen Deemed Of No Use 2Health News:Study Compares First-Line Drug Therapies For Treating HIV 2Health News:Study Compares First-Line Drug Therapies For Treating HIV 3Health News:Study Compares First-Line Drug Therapies For Treating HIV 4Health News:African-Americans Pose Less Questions To Treating Doctors 2Health News:Need for Newer AIDS Drugs In China 2
Smaller diameter wire probes & olive shape tips provide easier insertion through the lacrimal sac, 35cm (14 in) long, ID- .30mm (.012in); OD- .64mm (.025 in). S.S. Probes: .40mm x 11cm (27 G x 4 1/4...
...
Pre-set guard for precise depth incision, bi-directional blade can cut left or right. 250 micron....
Universal, clear, lightweight plastic with smooth edges & ventilation holes for patient comfort...
Medicine Products: